Drug Profile
Research programme: Nitrogen oxide neutralisers - Medinox
Latest Information Update: 29 Jul 2011
Price :
$50
*
At a glance
- Originator Medinox
- Class Thiocarbamates
- Mechanism of Action Nitric oxide inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 29 Jul 2011 No development reported - Preclinical for Type-2 diabetes mellitus in USA (PO)
- 06 Aug 2003 This compound is still in active development
- 12 Jun 2002 Phase-I clinical trial of NOX 700 in Type-2 diabetes mellitus in Netherlands (PO)